Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 DR5 (Drozitumab) h(28OXζ), which is constructed for the engineering of T cells to target human DR5. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-DR5 antibody linked to a CD28 transmembrane domain/ endodomain and OX40, CD3-zeta signaling domains. And the vector product was designed for the treatment of colorectal cancer, hepatocellular carcinoma, glioma, renal cancer, breast cancer.
|
Fig.2 The growth of three different established patient-derived xenografts is inhibited by treatment with drozitumab. SCID mice implanted with tumors. Eng, Jason W-L., et al. "Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5." Journal for immunotherapy of cancer 4 (2016): 1-11. Distributed under Open Access license CC BY 4.0, without modification. |
|
Fig.3 Cancer stems cells undergo apoptosis following treatment with drozitumab. Dissociated tumor cells from 11424, 14244 and 12424 treated in vitro with 10 μg/ml of drozitumab antibody for 1 h and incubated for 7 h with 10 μg/ml of anti-human Fc IgG antibody. Eng, Jason W-L., et al. "Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5." Journal for immunotherapy of cancer 4 (2016): 1-11. Distributed under Open Access license CC BY 4.0, without modification. |
|
Fig.4 Mice were treated with 200 μg drozitumab and tumors were resected, disaggregated and percentage of cleaved caspase-3 in CSCs vs. bulk tumor cells analyzed by flow cytometry. Treatment of tumor bearing mice in vivo with drozitumab induces apoptosis primarily in triple positive cells. Eng, Jason W-L., et al. "Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5." Journal for immunotherapy of cancer 4 (2016): 1-11. Distributed under Open Access license CC BY 4.0, without modification. |
|
Fig.5 Drozitumab treatment depletes DR5+ cells in vitro. Experiment performed twice in triplicate. Eng, Jason W-L., et al. "Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5." Journal for immunotherapy of cancer 4 (2016): 1-11. Distributed under Open Access license CC BY 4.0, without modification. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-DR5 (Drozitumab) h(CD28-OX40-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX444). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
